Aceso Life Science Group Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	7.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	11.9yrs

Jüngste Management Updates

Recent updates

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Feb 23

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Jan 01

Geschäftsführer

Aceso Life Science Group hat keinen Geschäftsführer, oder es liegen keine verfügbaren Daten vor.

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Chi Tak Fok	CFO & Executive Director	13.6yrs	HK$6.10m	0.82% HK$ 7.6m
Shao Yu Li	Senior Consultant	8.8yrs	HK$13.20m	57.52% HK$ 530.8m
Zhiliang Ou	Executive Director	no data	HK$600.00k	0.0099% HK$ 91.7k
Xiaodong Liu	Chief Operating Officer	5.8yrs	keine Daten	keine Daten
Chun Law	Group Financial Controller	7.7yrs	keine Daten	keine Daten
Chun Pong Siu	Company Secretary	1.9yrs	keine Daten	keine Daten

7.7yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von 474 ist erfahren und erfahren (durchschnittliche Amtszeit: 7.5 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Chi Tak Fok	CFO & Executive Director	10.8yrs	HK$6.10m	0.82% HK$ 7.6m
Zhiliang Ou	Executive Director	12.1yrs	HK$600.00k	0.0099% HK$ 91.7k
Kwan Sing Lam	Independent Non-Executive Director	11.9yrs	HK$200.00k	0.0099% HK$ 91.7k
Ming Sun Chan	Independent Non-Executive Director	12.3yrs	HK$200.00k	0.0099% HK$ 91.7k
Yiu Tong Mak	Independent Non-Executive Director	3yrs	HK$200.00k	keine Daten

11.9yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrener Vorstand: 474Die Vorstandsmitglieder sind sehr erfahren ( 11.8 ).

Aceso Life Science Group Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director

Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023

Aceso Life Science Group Limited Announces Change of Company Secretary

Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022

Senior Consultant recently bought HK$18m worth of stock

Senior Consultant recently bought HK$4.6m worth of stock

Recent updates

New major risk - Revenue and earnings growth

Aceso Life Science Group Limited to Report Fiscal Year 2024 Final Results on Jun 26, 2024

Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director

First half 2024 earnings released: HK$0.028 loss per share (vs HK$0.007 loss in 1H 2023)

New major risk - Revenue size

Aceso Life Science Group Limited Provides Group Earnings Guidance for the Six Months Ended 30 September 2023

Aceso Life Science Group Limited to Report First Half, 2024 Results on Nov 28, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited to Report Fiscal Year 2023 Results on Jun 28, 2023

New minor risk - Market cap size

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

Aceso Life Science Group Limited Consolidated Earnings Guidance for the Six Months Ended 30 September 2022

Aceso Life Science Group Limited to Report First Half, 2023 Results on Nov 29, 2022

Aceso Life Science Group Limited (SEHK:474) agreed to acquire 4% stake in Quanzhou Donghai Bay Asset Management Company Limited for approximately CNY180 million.

Aceso Life Science Group Limited Announces Change of Company Secretary

Full year 2022 earnings released: HK$0.051 loss per share (vs HK$0.057 loss in FY 2021)

Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022

Full year 2022 earnings released

Aceso Life Science Group Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Aceso Life Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2022

Senior Consultant recently bought HK$18m worth of stock

Senior Consultant recently bought HK$4.6m worth of stock

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Non-Executive Director Yao Li has left the company

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Senior Consultant recently sold HK$5.0m worth of stock

First half 2021 earnings released: HK$0.07 loss per share

New 90-day low: HK$0.23

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.07 loss per share

Aceso Life Science Group Limited to Report First Half, 2021 Results on Nov 25, 2020

New 90-day low: HK$0.28

Senior Consultant recently bought HK$852k worth of stock

Hao Tian Development Group Limited has completed a Follow-on Equity Offering in the amount of HKD 150 million.

Senior Consultant recently bought HK$2.8m worth of stock

New 90-day high - HK$0.34

Full year earnings released - HK$0.049 loss per share

Hao Tian Development Group Limited to Report Fiscal Year 2020 Results on Jun 29, 2020

Geschäftsführer

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter